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Abstract
Background: Regulatory T cells (Tregs) are essential in the control of tolerance. Evidence implicates Tregs in human
autoimmune conditions. Here we investigated their role in systemic sclerosis (SSc).
Methods/Principal Findings: Patients were subdivided as having limited cutaneous SSc (lcSSc, n=20) or diffuse cutaneous
SSc (dcSSc, n=48). Further subdivision was made between early dcSSc (n=24) and late dcSSc (n=24) based upon the
duration of disease. 26 controls were studied for comparison. CD3+ cells were isolated using FACS and subsequently
studied for the expression of CD4, CD8, CD25, FoxP3, CD127, CD62L, GITR, CD69 using flow cytometry. T cell suppression
assays were performed using sorted CD4CD25
highCD127
- and CD4CD25
lowCD127
high and CD3
+ cells. Suppressive function
was correlated with CD69 surface expression and TGFb secretion/expression. The frequency of CD4
+CD25
+ and
CD25
highFoxP3
highCD127
neg T cells was highly increased in all SSc subgroups. Although the expression of CD25 and GITR
was comparable between groups, expression of CD62L and CD69 was dramatically lower in SSc patients, which correlated
with a diminished suppressive function. Co-incubation of Tregs from healthy donors with plasma from SSc patients fully
abrogated suppressive activity. Activation of Tregs from healthy donors or SSc patients with PHA significantly up regulated
CD69 expression that could be inhibited by SSc plasma.
Conclusions/Significance: These results indicate that soluble factors in SSc plasma inhibit Treg function specifically that is
associated with altered Treg CD69 and TGFb expression. These data suggest that a defective Treg function may underlie the
immune dysfunction in systemic sclerosis.
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Introduction
Over the past decade, there have been tremendous advances in
our understanding of the basic processes that control immune
tolerance. It is now generally accepted that auto-reactive T cells
are present in healthy individuals, but that there mere presence
does not necessitate the development of autoimmune disease. The
identification of CD4+CD25+ regulatory T cells (Tregs) as a
crucial component of self-tolerance has opened a major area of
investigation and numerous studies have demonstrated the potent
influence of Tregs in suppressing autoimmune disease, transplan-
tation and graft-versus-host disease [1,2,3,4,5,6,7]. Studies in
rodents have provided the first evidence for the existence of a
naturally occurring population of CD4+CD25+ professional
regulatory/suppressor T cells, which upon in vitro TCR-mediated
stimulation, suppress proliferation of effector T cells [3,8]. In the
periphery of young mice not prone to autoimmune disease, Tregs
constitute a stable 10% of CD4+ T cells. In contrast, mice
genetically prone to autoimmune disease such as diabetes have
markedly diminished circulating Tregs [9,10].
Tregs have unique and robust immunosuppressive activity. The
cells require specific TCR-mediated activation to develop
regulatory capacity, but their effector function appears to be
nonspecific, regulating local inflammatory responses through a
combination of cell-cell contact and suppressive cytokine produc-
tion [11,12]. In addition to naturally occurring Tregs, several
therapeutic interventions promote Treg development and function
[13]. These so-called ‘‘adaptive’’ Treg populations share many
features attributed to natural occurring Tregs, but can differ in
critical cell surface markers [14].
In humans, the important role of Tregs in various autoimmune
diseases has been underscored by numerous seminal studies. For
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5981instance, Tregs derived from patients with rheumatoid arthritis
(RA) are defective in their ability to suppress cytokine production
and to convey a suppressive phenotype to CD4+ effector T cells,
which was at least partly restored upon treatment of TNFa
neutralizing therapies [15]. Moreover, the interaction of Tregs
with activated monocytes from patients with RA even led to a
diminished suppressive activity possibly underlying their dimin-
ished capacity in vivo [16]. Likewise, it was demonstrated by several
groups that the number and suppressive capacity of Tregs is
altered in patients with systemic lupus erythematosus [17,18,19].
Systemic sclerosis (SSc) is a complex autoimmune disease
characterized by an excessive deposition of matrix molecules,
leading to fibrosis of multiple organs including the skin, lungs,
heart and gastrointestinal tract, and often leading to severe
morbidity and premature death. Although the role of immune
dysfunction in the pathogenesis of SSc is currently not well
understood, alterations in cellular immunity are typified by
aberrant T cell biology both in the skin as well as circulation of
SSc patients. For example, CD4+ T cells are increased in the
circulation of SSc patients [20,21], whereas NKT cells and c/d T
cells are decreased [22]. In addition, lesional skin from SSc
patients displays various features consistent with T cell activation
[21,23,24]. Finally, circulating T cells from SSc patients show
altered secretion of various inflammatory mediators compared to
T cells from healthy controls [25,26].
T cell priming by professional antigen presenting cells is tuned
by an orchestra of inflammatory mediators, of which TGFb, IL-
23, IL-6, IL-22 and IL-1a are considered the most influential. For
instance, in the absence of other pro-inflammatory mediators,
TGFb production by dendritic cells induces FoxP3, a Treg marker
[27,28]. In contrast, TGFb in combination with IL-1a, IL-6 or IL-
23 drives the expression of RORcT, a proliferation factor specific
for the recently identified Th17 subset [29,30,31,32]. Intriguingly,
IL-23, IL-1a and IL-17 have been found increased in the
circulation of SSc patients compared to healthy controls
[33,34,35,36]. Although TGFb is not increased in SSc plasma,
multiple studies have strongly implicated this cytokine as a major
stimulus of fibrosis in involved organs. Together, these observa-
tions suggest that altered Treg function might play a key role in
SSc pathogenesis. To address this issue, we set out to investigate
changes in the number and/or function of Tregs in the peripheral
blood of patients with SSc, taking into account the different disease
phenotypes. In this paper, we show that Tregs are more frequent
in SSc patients but are defective in their capacity to suppress
proliferation of CD4+ effector T cells. We go on to demonstrate
that this diminished suppressive effect of Tregs in SSc is associated
with markedly lower expression of the activation marker CD69.
Finally, we show that the diminished suppressive capacity and
absent upregulation of CD69 upon activation is dependent upon
soluble factors present in the plasma of SSc patients. Together
these data suggest that diminished T regulatory capacity is present
in SSc and that the regulatory deficiency is due to circulating
factors rather than an inherent defect of Tregs.
Methods
Ethical review board statement
All samples were obtained with written informed consent after
approval of the Institutional Review Board at the Boston
University School of Medicine, Lund Univeristy medical Hospital
and the Radboud University Nijmegen Medical Center.
Study population. Sixty-eight patients presenting to the
Arthritis Center, Boston Medical Center were included in the
study. This study was approved by the Boston University Medical
Center Institutional Review Board. All of the patients met the
American College of Rheumatology preliminary criteria for the
classification of SSc [37]. Patients were subdivided as having
limited cutaneous SSc (lcSSc, n=20) or diffuse cutaneous SSc
(dcSSc, n=48) on the basis of the extent of their skin involvement
[38]. A further subdivision was made between early dcSSc (n=24)
and late dcSSc (n=24) based upon the duration of disease,
defining early dcSSc as patients having a disease duration ,2
years and late dcSSc as patients having a disease duration longer
than 3 years. As a comparator group 26 healthy controls were
studied. Patients were allowed to use low-dose prednisolone (,10
mg daily) at inclusion of the study. Patients receiving higher doses
were excluded.
Monoclonal antibodies. For immunostaining and analysis
by fluorescence-activated cell sorting (FACS), we used
phycoerythrin (PE), allophycocyanin (APC) and fluorescein
isothiocynate (FITC) conjugated mouse monoclonal antibodies
(mAb) against human CD4, CD8, CD25, CD69, GITR (Miltenyi
Biotec Inc., CA, USA), CD127 (eBioscience, CA, USA), CD62
(BD Bioscience, NJ, USA). Intracellular staining of CD4+CD25+
cells for FoxP3 was performed using the intracellular fixation and
staining procedures according to the manufacturer’s protocols.
Corresponding mouse/rat isotype controls were included in the
analyses.
Isolation of PBMCs, CD3
+ cells and
flowcytometry. PBMCs were isolated from heparinized
venous blood by using density-gradient centrifugation over
Ficoll-Paque (Amersham Bioscience). Next, CD3+ cells were
isolated from PBMCs using CD3 microbeads according to
manufacturer’s protocol (Miltenyi Biotec). To this aim, 10 x 10
4
CD3+ cells were re-suspended in 100 ml buffer (PBS + 1% BSA)
on ice. After isolation, cells were directly transferred into RPMI
1640 media supplemented with 2nM L-glutamine, 100 U/mL/ml
penicillin/streptomycin (Life technologies), and 10% FBS
(BioWhitacker) in 96-well U-bottom plates (Nunc). For
flowcytometric analysis, CD3+ were kept on ice and washed
extensively with citrated PBS containing 1% FCS. Than, after
using the protocol for fixation, intra-cellular staining was achieved
using 10 ml of FITC, APC or PE- conjugated antibody that was
added and incubated on ice for 20 min. 300 ml FACS buffer was
than added and T cells were pelleted, resuspended in 200 ml
buffer, and stained for the intracellular marker FoxP3/TGFb were
appropriate as conducted by the recommended procedure
obtained from the manufacturer (Miltenyi Biotec Inc., CA,
USA). Thereafter, cells were washed in buffer, fixed with 2%
formaldehyde, washed again in buffer and stored at 4uC. The cells
were analyzed using a LSRII FACScan flow cytometer (BD
Biosciences) and data were processed using FlowJo software. In all
experiments, the purity of CD3+, CD25
highCD127
low and
CD25
lowCD127
high cells was .97%.
Sorting of CD25
high and CD127
low cells for T cell
suppression assays. For the T cell suppression assay,
CD25
highCD127
low cells were immediately incubated with
CD25-PE and CD127-FITC (eBioscience, CA, USA) antibodies
for 20 minutes on ice after CD3 MACS bead isolation. Thereafter,
were sorted based upon the expression of CD25 and CD127.
CD25
highCD127
low cells, CD25
lowCD127
high cells and unsorted
CD3+ T cells were transferred into RPMI 1640 media
supplemented with 2nM L-glutamine, 100 U/mL/ml penicillin/
streptomycin (Life technologies), and 10% FCS (BioWhitacker) in
96-well U-bottom plates (Nunc) until further use (overnight
incubation). To assess the suppressive capacity of Treg
(CD25
highCD127
low) and non-Treg (CD25
lowCD127
high) cells on
unsorted CD3+ cells, unsorted T cells were brought to a
Dysfunction of Tregs in SSc
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6 cells/ml and subsequently stimulated with
phytohaemaglutinin (Sigma-Aldrich Corp, MO, USA). Both Tregs
and non-Tregs from healthy controls and SSc patients were added
to autologous unsorted CD3
+ cells at fixed ratios 1:20 for 5
consecutive days. After 4 d of culture, [3H]Tdr was added for the
remaining 24 hrs of cultures. The cells were harvested onto glass
fiber filters and [
3H]thymidine incorporation was assessed on a
beta scintillation counter.
Assessment of T cell suppressive effect and CD69
inducing capacity of SSc plasma. The effect of SSc plasma
on the suppressive capacity of healthy Treg was investigated by co-
incubation with 10% or 25% plasma from edSSc patients during
whole experiment. For these experiments plasma was taken from
the SSc patients and healthy controls at the same time point as the
T cell experiments were performed. The plasma was stored at -
80uC until further use. Plasma from 4 different edSSc patients was
used in various independent experiments. To assess the CD69
inducing capacity of SSc plasma CD3+ cells and CD25
highCD127
-
cells were used from healthy controls and SSc patients. For this
aim, both cell populations were cultured in RPMI 1640 media
supplemented with 2nM L-glutamine, 100 U/mL/ml penicillin/
streptomycin (Life technologies), and 10% FBS (BioWhitacker) in
a 96 wells plate for 12 hours. Subsequently, CD3+ cells and
CD25
highCD127
- cells were stimulated with either
phytohaemaglutinin (PHA) only, PHA in combination with 10%
plasma from an early dcSSc or plasma alone. After 12 hours of
stimulation cells were analyzed on expression of CD69 by
flowcytometry as previously described.
Measurement of soluble and intracellular
TGFb. Intracellular TGFb expression in CD25
highCD127
- cells
was investigated using a monoclonal antibody for TGFb (BD
Bioscience, NJ, USA) and the intracellular staining protocol as
used for the FoxP3 staining. After the staining protocol, cells were
fixed with 2% formaldehyde, stored at 4uC and analyzed on a flow
cytometer the next day. TGFb was assayed using mink lung
epithelial cells stably transfected with a plasminogen activator
inhibitor-1 promoter/luciferase reporter plasmid (provided by D.
Rifkin) as described previously by Abe et al [39].
Statistical analysis. Values are shown throughout the paper
as mean6sem. Proportions of lymphocyte subpopulations were
compared using the Student’s t test for normally or not normally
distributed populations where appropriate. Relationships between
different values were examined using Pearson’s correlation
coefficient and Spearman’s rank correlation tests. All statistical
analyses were performed using Graphpad Prism (GraphPad Prism
4.0 by Graph Pad software Inc.)
Results
CD4
+CD25
+FoxP3
+CD127
- cells are markedly increased in
the circulation of SSc patients irrespective of disease
phenotype
Human peripheral blood contains a heterogeneous subset of
CD4+CD25+ T cells that comprises T regulatory cells (Tregs) and
a substantial number of activated effector T cells. To date, the
expression of FoxP3 and CD127 remain the best and most specific
markers of Tregs [40,41]. Since we postulated that the number
and/or phenotype of Tregs in SSc is altered compared to controls,
but may also differ among different clinical SSc subtypes, we here
studied the number and phenotype of Tregs from patients with
limited cutaneous SSc (n=20), late diffuse cutaneous SSc (n=24)
and early diffuse SSc (n=24) in comparison with those from
healthy controls (n=26). The clinical characteristics of all patients
included in this study are presented in Table 1. Despite similar
absolute numbers of CD3+ cells, flowcytometric analysis with the
markers CD4, CD25, FoxP3 and CD127, demonstrated that both
CD4
+CD25
+ (12.461.0 vs. 27.562.8, P,0.0001) and
CD25
+FoxP3
+CD127
- (2.960.5 vs. 17.361.9, P,0.0001) cells,
(further designated as Tregs) are markedly increased in the
circulation of SSc patients compared to controls (Figure 1a, b).
Further stratification to SSc disease phenotype revealed a
significantly higher number of CD4
+CD25
+ (P=0.01) and
CD25
+FoxP3
+CD127
- (P=0.01) in SSc patients with edSSc
compared to ldSSc (Figure 1b), but no other significant
differences between SSc phenotypes were detected. Notably, two
patients with ldSSc and two with edSSc received cyclophospha-
mide pulse therapy for their disease. Whereas both ldSSc
responded clinically well only one patient with edSSc did. In
these three patients the percentage CD25
+FoxP3
+CD127
- cells
was much lower (6.062.1) compared with the other patients that
were not treated. The edSSc patient that received cyclophospha-
mide pulse therapy but did not show a clinical response showed a
frequency of 22.8% CD25
+FoxP3
+CD127
- cells. All the patients
had received cyclophosphamide longer than 3 months ago.
Further analysis focusing on CD25+
bright (top 10%) and
CD25+
very bright (top 2%) cells revealed a similar expression of
the markers FoxP3 and CD127 among all individuals, both on the
levels of percentage positive cells (Figure 1c, d), as well on the
mean fluorescence intensity (MFI, data not shown). Taken
together, these data suggest that SSc patients have a markedly
increased frequency of T regulatory cells, which is not related to
an altered expression of markers characterizing Treg phenotype.
Aberrant expression of phenotypic markers CD62L and
CD69 on CD25+FoxP3
bright and CD25+FoxP3+
verybright
from SSc patients
Although we observed a markedly increased frequency of
CD25
+FoxP3
+CD127
- cells phenotypically representing Tregs in
SSc, these patients continue to have active disease suggesting
altered T cell suppressive activity. To address this, we next
investigated the expression of markers potentially reflecting T
cell activation including GITR, CD62L and CD69. Although
the function of glucocorticoid-induced tumor necrosis factor
receptor related protein (GITR) remains to be fully elucidated, it
is generally accepted that GITR expression is increased upon
TCR engagement, reflecting T cell activation [42]. As expected,
GITR expression on CD25+Foxp3+, CD25+FoxP3+
bright and
CD25+FoxP3+
verybright from healthy donors gradiently increased
using flowcytometry (Figure 2a). In addition, the expression of
GITR on CD25+FoxP3+, CD25+FoxP3+
bright and
CD25+FoxP3+
verybright was comparable between healthy controls
and SSc patients and among the investigated SSc phenotypes. In
contrast, the expression of CD62L and CD69 was markedly
lower in SSc patients compared to healthy controls (Figure 2b,
c). CD62L is a L-selectin that is upregulated upon Treg
activation and highly critical for Tregs to enter the lymph node
and to carry out their local suppressive function [43,44]. CD69
expression is pivotal for Treg function, potentially via upregula-
tion of TGFb production upon cross-linking [45,46]. CD69 on
CD25
high (37.065 vs. 17.665 vs. 5.362) and CD25
veryhigh
(35.168 vs. 17.865.7 vs. 2.460.9) T cells significantly decreased
in a step-like manner, comparing healthy controls to patients
with lSSc, ldSSc and edSSc phenotypes. Intriguingly, and in line
with that observed in other autoimmune diseases, the expression
of CD69 on CD4
+ effector T cells was significantly increased in
all SSc patients compared to controls and followed an inverse
correlation with the CD69 expression on CD25
high or FoxP3
high
cells suggesting, that the regulation of CD69 expression is
Dysfunction of Tregs in SSc
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(Figure 2d). In the search for potential SSc characteristics that
might correlate with CD69 on Tregs in SSc, we found a
significant association between the disease duration in lSSc
patients whereas no association was present in patients either
with ldSSc or edSSc (Figure 2e).
Figure 1. Increased presence of CD4
+CD25
+ and CD25
highFoxP3
highCD127
- cells in the circulation of patients with systemic sclerosis
(SSc). Flow cytometry analysis of and CD4
+CD25
+ and CD25
highFoxP3
highCD127
- cells was performed in healthy controls (n=26) and patients (n=68)
with different phenotypes of SSc. Peripheral blood mononuclear cells (PBMC’s) were stained with anti-CD4, anti-CD25, anti-CD127 and anti-FoxP3,
and analyzed by flow cytometry. (a) One representative individual from each group is shown. (b) Percentage of CD4+CD25+ and CD25+FoxP3+ cells
are presented for each group, consisting of healthy controls (n=26), lSSc (n=20), ldSSc (n=24) and edSSc (n=24) patients. (c) Based upon CD25
expression, the top 10% (CD25
bright) and top 2% (CD25
verybright) were gated and FoxP3 expression analyzed as the percentage positive cells. (d) Based
upon FoxP3 expression, the top 10% (FoxP3
bright) and top 2% (FoxP3
verybright) were gated and CD127 expression analyzed as the percentage positive
cells. Data is presented as mean6sem.
doi:10.1371/journal.pone.0005981.g001
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+FoxP3
+CD127
-
regulatory T cells from SSc patients is correlated with
CD69 expression and TGFb levels
Taken together, our observations imply that although SSc
patients have a significantly increased number of
CD25
+FoxP3
+CD127
- cells in the circulation, these cells
phenotypically have markers suggesting impaired suppressive
activity. To test the regulatory activity of these cells, we studied
the capacity of CD25
highCD127
low cells from healthy controls
(n=8), lSSc (n=6), ldSSc (n=9) and edSSc (n=8) patients to
suppress the proliferation of CD4
+ effector cells. As expected,
Tregs from healthy controls efficiently suppressed the prolifer-
ation of CD4+ effector cells by 87.3%64.9, whereas non-
regulatory T cells (CD25
lowCD127
high) did not (8.5%62.8). In
contrast, Tregs obtained from SSc patients all had a markedly
diminished suppressive capacity compared to those from healthy
donors (Figure 3a) with T regs from lSSc, edSSc and ldSSc
suppressing CD4+ effector cell proliferation by, respectively,
28.2%66.0 (P=0.0001), 56.0%68.5 (P=0.006) and 18.3%65.2
(P,0.0001). Since CD69 expression by Tregs has been
associated with the production of TGFb [46], one of key
molecules implicated in suppressor activity, we investigated the
possible relationship between CD69 expression and the dimin-
ished suppressive effect observed in SSc. Interestingly, the
suppressive capacity correlated significantly with CD69 expres-
sion in all groups (Figure 3b).
We next investigated the expression levels of TGFb in the Tregs
from SSc patients compared to healthy controls and their
CD45Ra+ cells. In line with the CD69, which was specifically
lower on regulatory T cells in SSc, also TGFb expression was
significantly decreased by regulatory T cells obtained from SSc
patients compared to those from healthy controls (Figure 3c).
TGFb expression on Tregs from ldSSc and edSSc patients was
significantly lower compared to that from patients with lSSc
(P=0.008), whereas no difference was observed between ldSSc
and edSSc. Measurement of soluble TGFb in the supernatant
revealed no measurable TGFb, suggesting that TGFb confers its
effect as membrane-bound (data not shown).
A fraction smaller than 10kD in SSc plasma inhibits the
suppressive capacity of regulatory T cells and abrogates
the upregulation of CD69 specifically on regulatory T
cells
As inflammatory cytokines play an important role in the
pathogenesis of SSc and regulatory T cell function, we next
investigated whether the diminished suppressive effect of Tregs
from SSc could be carried over by soluble factors in the circulation
of SSc patients or alternatively could be due to an inherent defect
in Tregs. Unexpectedly, the addition of 10% plasma from edSSc
patients completely abrogated the suppressive capacity of Tregs on
CD4+ effectors cells from healthy controls, an observation that
was highly consistent throughout 5 experiments using plasma
samples from 5 edSSc and 2 ldSSc patients (Figure 4a). The
addition of 25% plasma had a similar effect although somewhat
less potent as 10% plasma, a phenomenon that was probably
caused by the TGFb present in patients plasma, that partly
restored the suppressive capacity of Tregs. In contrast, the
addition of plasma obtained from healthy controls did not have
a significant effect on the suppressive capacity of Tregs.
Based on our observations that CD69 expression correlates with
the diminished suppressive capacity in SSc, we hypothesized that
the plasma of SSc patients had a direct effect on the regulation of
CD69 expression. To test this, we stimulated freshly isolated
CD3+ cells and CD25
highCD127
low T cells from healthy controls
with the potent T cell activator PHA. PHA markedly induced
CD69 expression both on CD3+ and CD25
highCD127
low T cells
(Figure 4b). However, plasma from edSSc patients also
significantly increased CD69 expression on CD3+ cells
(P=0.0007) and had an additive effect in combination with
PHA (P=0.02). In contrast with the effect of plasma on CD3+
cells, the addition of edSSc plasma to CD25
highCD127
low T cells
did not increase CD69 expression. More intriguingly, the addition
Table 1. Patients clinical characteristics.
Limited cutaneous SSc Late diffuse cutaneous SSc Early diffuse cutaneous SSc
Number 20 24 24
N females (%) 12 (92) 11 (79) 12 (80)
Age at onset 43.8613.4 38.6612.3 48.169.2
Disease duration 9.569.8 8.366.2 1.260.8
ANA positivity 100% 60% 93%
mRSS at inclusion not assessed 17.668.6* 23.468.7*
Pulmonary hypertension 30% 13% 8%
Lung fibrosis 20% 52% 34%
Current Therapies
MMF 0% 36% 27%
Cyclophosphamide 0% 14% 13%
Prednisolone 23% 29% 47%
Hydroxychloroquine 15% 7% 0%
Anti-IL-3 0% 0% 7%
Methotrexate 0% 0% 0%
Tacrolimus 7% 0% 0%
*P value 0.03.
doi:10.1371/journal.pone.0005981.t001
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figure depicts the expression of the T cell activation marker GITR on CD25+, CD25
bright and CD25
verybright cells from healthy controls (white bars,
n=24) and SSc patients having limited cutaneous SSc (light gray bars, n=18), late diffuse SSc (dark gray bars, n=22) and early diffuse SSc (black bars,
n=22) patients. In panel (b) the expression of CD62L on Tregs is investigated. CD25+ and CD25
bright cells from SSc and healthy controls express
similar levels of CD62L, whereas CD25
verybright from SSc patient subsets exhibit lower levels of CD62L compared to those from healthy controls. Panel
(c) reflects the expression of CD69 on Tregs from healthy donors and SSc patients. CD25+, CD25
bright and CD25
verybright cells from SSc patients express
significant lower levels of CD69 than those from healthy donors. CD69 expression on CD25
bright and CD25
verybright cells from edSSc patients was
significantly lower then that from ldSSc patients, and ldSSc expressed CD69 significantly lower than those from lSSc. In panel (d) the expression on
CD3+ cells is shown for all investigated groups. In contrast with that observed on Tregs from SSc patients, CD69 expression on CD4+ cells was
significantly higher in all SSc patient groups. Panel (e) reflects the potential association between CD69 expression on Tregs and disease duration.
CD69 expression on T regs from patients with lSSc correlated with disease duration, whereas this was not the case either with ldSSc nor edSSc. In all
figures the white bars represent healthy controls, whereas lSSc, ldSSc and edSSc patients are represented by light gray, dark gray and black bars,
respectively.
doi:10.1371/journal.pone.0005981.g002
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expression of TGFb. Unsorted CD3+ (MACS bead isolated) were stimulated with PHA (5 mg/ml) and consecutively incubated with CD25
highCD127
-
or CD25
lowCD127
high cells for 5 days. Thereafter, CD3+ cells were incubated with 3
H-thymidine for 24 more hours after which 3
H-thymidine
incorporation was measured. Panel (a) reflects the suppressive capacity of Tregs from healthy donors and SSc patients. Proliferation of CD3+ effector
cells was effectively inhibited by T regulatory cells from healthy controls, whereas a clearly diminished suppressive activity was observed in the
experiments with Tregs from SSc patients. Suppressive effect of Treg (CD25
highCD127
-) and non-Tregs (CD25
lowCD127
high) is presented in black and
white bars, respectively. Results are the mean and SEM of 6 separate experiments using cells from healthy donors (n=9), lSSc (n=7), ldSSc (n=9) and
edSSc (n=7). Panel (b) represents the correlation of CD69 expression and Treg suppressive capacity in Tregs from the various groups under
investigation. The percentage of CD69 positive regulatory T cells (CD25
highCD127
-) correlates well with the percentage of inhibition of CD3+ cells in
healthy controls (triangles), lSSc (diamonds), ldSSc (circles) and edSSc (squares). Panel (c) reflects the expression of intracellular TGFb in Tregs from
healthy controls and SSc patients as measured using intracellular flow cytometry. CD25
highCD127
- cells from all SSc patients express lower TGFb levels
compared to controls. Left panel reflects an representative individual from each group whereas the right panel displays the mean of each group
comprising 6 individuals (per group) coming forth from 4 independent experiments.
doi:10.1371/journal.pone.0005981.g003
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PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e5981Figure 4. Plasma from SSc patients abrogates T cell suppression and up regulates CD69. (a) During the co-cultures of unsorted CD3+ cells
with either Tregs (CD25
highCD127
-) or non-Tregs (CD25
lowCD127
high) 10 or 25% plasma from an edSSc patient or healthy control was added to the
culture. The graph represents data from 3 independent experiments using 3 healthy control cells, and plasma derived from two edSSc patients and
two control individuals. (b) The effect of SSc plasma was evaluated by adding 10% to CD3+ cells for 24 hrs stimulated with PHA or unstimulated. As a
control, CD69 expression was measured on CD3+ cells stimulated with PHA only. CD4 and CD25
high/FoxP3
high cells were gated based on the
expression of these markers using flow cytometry. (c) CD69 expression and induction upon PHA mediated stimulation of CD4+ and CD25
high/
FoxP3
high obtained from healthy donors, lSSc, ldSSc and edSSc patients was investigated using flow cytometry. One representative patient from each
group is shown.
doi:10.1371/journal.pone.0005981.g004
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highCD127
low T cells stimulated with PHA
completely abrogated the effect of PHA. Since we observed a
lower CD69 expression on regulatory T cells freshly isolated from
SSc patients, we studied whether these cells still possess the ability
to increase CD69 expression upon activation. Co-incubation of
regulatory T cells either from patients with lSSc, ldSSc or edSSc
led to an clear increase of CD69 expression that could be inhibited
by plasma from edSSc patients (Figure 4c). In all experiments
presented here, plasma from healthy controls was taken into
account but did sort any inhibitory effects as that observed from
SSc patients.
Discussion
SSc is an autoimmune disease that reflects several features
suggesting dysregulated T cell activation [24,50,51]. The data
presented here suggest that dysfunctional Tregs may play an
important role in SSc. We show that although the number of
Tregs is markedly increased in all clinical SSc phenotypes, these
Tregs have a diminished capacity to control CD4 effector T cells.
Further we show that their defective function correlates with lower
expression of CD69 and TGFb.
Tregs have not been previously characterized in patients with
SSc; however, they are critical in maintaining self tolerance and
preventing autoimmunity. In several other autoimmune disease
Tregs have been implicated in pathogenesis. For example, lupus
prone mice, depleted of CD4
+CD25
+ cells by thymectomy, have
enhanced expansion of autoreactive T cells and accelerated
autoantibody production [52]. Conversely, restoration of the
CD4
+CD25
+ cell population from syngeneic normal mice
effectively abrogates the development of autoimmune disease, as
has treatment with in vitro expanded Tregs [52,53,54]. Similar
evidence originates from experimental arthritis, diabetes and
multiple sclerosis models, further highlighting the crucial role of
the Tregs in controlling the delicate balance between tolerance
and autoimmunity. More recently, several studies performed in
patients with systemic lupus erythematosus (SLE) and rheumatoid
arthritis (RA) revealed an aberrant frequency and/or function of
Tregs thus indicating their crucial role in human diseases
[18,19,55,56,57]. However, none of these studies reported the
markedly increased frequency of CD4
+CD25
+ and CD25
+/
FoxP3
+CD127
- cells found in our study. In contrast, although
some inconsistencies exist, most of these studies found a decreased
frequency of circulating Tregs. There appear to be some
discrepancies in the literature based on the sole use of CD4 and
CD25 as markers for Tregs. However, co-expression of CD4 and
CD25 can be induced upon multiple inflammatory events and
does not necessarily guarantee suppressive capacity. Therefore, the
limited use of these markers could merely reflect activation and
thus lead to a false assessment of elevated Treg numbers. More
recently, it has been shown that the combination of FoxP3 and
CD127 expression is highly specific for discriminating Tregs from
activated T cells. FoxP3 expression correlated inversely with
CD127 expression, and CD4+CD25
highFoxP3
highCD127
low cells
were found to have the most potent suppressive activity [40,58]. In
the current study the combination of all these markers was used to
characterize and isolate regulatory T cells, confirming our
observations of a markedly increased frequency of circulating
Tregs in SSc patients.
TGFb is known to potently induce expression of the
proliferation factor FoxP3, characterizing Tregs. As TGFb is
generally accepted as the key regulator of SSc pathogenesis, the
increased frequency of Tregs in SSc was not surprising. TGFb is
crucial in the induction of FoxP3 expression and induction of
suppressive activity by conversion of CD4+CD25- T cells [59].
Therefore, increased TGFb found in SSc might drive the
increased frequency of CD25
highFoxP3
highCD127
-. Indeed, our
observation of increased FoxP3, despite comparable levels of
CD25 and GITR expression in SSc patients, suggests that Tregs
from SSc patients are activated to some extent. The observation
that CD62L, a marker that is highly expressed on naturally
occurring (thymically-derived) regulatory T cells, is lower in SSc
patients suggests that these Tregs originate through conversion of
CD4
+CD25
- T cells. These so-called ‘‘adaptive’’ Tregs share many
features with naturally occurring Tregs, but can differ in critical
cell surface biomarkers and functional attributes [14]. For
instance, Tregs can mediate their suppressive effects through the
production of IL-10 versus TGFb [60,61].
In contrast to CD25 and GITR expression, CD69 expression
on Tregs was significantly lower in SSc patients and correlated
closely with diminished suppressive activity. Further, upregulation
of CD69 by T cell stimulation was completely abrogated by
plasma from SSc patients, suggesting the presence of soluble
factors in SSc plasma that inhibit CD69 and consequently, the
suppressive capacity. Interestingly, the effect of plasma on CD69
expression was highly specific for Tregs, since CD69 regulation on
other T cells was not affected. SSc patients show many features
suggesting that autoimmune and inflammatory factors may
stimulate profibrotic organ damage. For instance, accumulating
evidence implicates inflammatory mediators in the Th17 pathway,
such as IL-6, IL-1a, IL-23 and IL-17 itself, but also those in the
Th2 (IL-10, IL-4), Th1 (IFNc) and other inflammatory pathways,
such as IFN type I and TNFa, in this condition (unpublished
results [33,34,35,36]). It is therefore tempting to speculate that
several mediators could inhibit Treg CD69 expression in SSc
patients. In this light, the observation that the three patients who
had a clinical response to treatment had a Treg frequency, CD69
expression and suppressive capacity that was almost comparable to
that observed in healthy controls is intriguing. Whether these
observations are related to lower levels of inflammatory mediators
in patients with a therapeutic response will require further
investigation.
The potential of Tregs to modulate immune responses has led to
considerable interest in their use for clinical intervention in
autoimmune diseases. Two broad therapeutic applications have
been considered: first, to expand the regulatory T cell compart-
ment ex vivo with the goal of re-infusion and second, to
manipulate the immune system in vivo resulting in an increase
of Tregs. The latter approach has been shown to be highly
applicable by seminal studies by Ehrenstein et al. in which a
monoclonal antibody against TNFa led to a re-occurrence of
CD4
+CD25
+CD62L
- T cells with high suppressive activity
[15,62]. Of interest for the current study the suppressive effects
of Tregs in these latter studies were found to be contact dependent
since the neutralization of TGFb and IL-10 did not block the
effect. This is consistent with our observation that intracellular
expression of TGFb on Tregs corresponded well with their
suppressive capacity, whereas no TGFb was found in the culture
supernatants. In our studies we demonstrate that a soluble factors
in the plasma of SSc patients is responsible for the dramatic effects
observed on suppressive activity, CD69 and TGFb expression. In
addition, we did not find evidence for an inherent defect in lower
Treg CD69 expression in SSc patients, since activation of these
cells led to increased expression.
The factors driving TGFb production are not well resolved. The
role of CD69 in the production of TGFb by T cells was shown in
several studies. For instance, it was demonstrated that CD69-/-
mice display greatly prolonged tumor survival that was related to a
Dysfunction of Tregs in SSc
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TGFb production by NK and T cells [63]. With respect to
autoimmunity, CD69-/- mice showed a higher incidence and
severity of collagen-induced arthritis, which again were correlated
with reduced levels of TGFb [46]. The observation that CD69
surface expression closely mirrors intra-cellular TGFb expression
both on CD45Ra as on CD25
highFoxP3
highCD127
- cells is in line
with the notion that CD69 is implicated in TGFb production by T
regs.
Altogether, our observations provide a rationale for therapeutic
intervention to restore suppressive activity by T regs in SSc. More
careful studies designed to identify the nature of factors that
moderate the effects in the circulation are warranted.
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